IFITM1 antibody (C-Term)
Quick Overview for IFITM1 antibody (C-Term) (ABIN3018715)
Target
See all IFITM1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Sequence
- CCLGFIAFAY SVKSRDRKMV GDVTGAQAYA STAKCLNIWA LILGILMTIG FILLLVFGSV TVYHIMLQII QEKRGY
-
Cross-Reactivity
- Human, Mouse
-
Characteristics
- Polyclonal Antibodies
-
Purification
- Affinity purification
-
Immunogen
- A synthetic peptide corresponding to a sequence within amino acids 50 to the C-terminus of human IFITM1 (NP_003632.3).
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB,1:200 - 1:2000,IHC,1:50 - 1:200
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
-
: "CRISPR/Cas9-mediated deletion of miR-146a enhances antiviral response in HIV-1 infected cells." in: Genes and immunity, (2018) (PubMed).
-
-
- IFITM1 (Interferon-Induced Transmembrane Protein 1 (IFITM1))
-
Alternative Name
- IFITM1
-
Background
- IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2, Marburg virus (MARV, Ebola virus (EBOV, Dengue virus (DNV, West Nile virus (WNV, human immunodeficiency virus type 1 (HIV-1 and hepatitis C virus (HCV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. Inhibits SARS-CoV-2 S protein-mediated syncytia formation. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome.,IFITM1,9-27,CD225,DSPA2a,IFI17,LEU13,Cancer,Tumor biomarkers,Tumor suppressors,p53 pathway,Signal Transduction,Immunology & Inflammation,CD markers,Cytokines,Interferons,Cell Intrinsic Innate Immunity Signaling Pathway,Stem Cells,IFITM1
-
Molecular Weight
- 13 kDa
-
Gene ID
- 8519
-
UniProt
- P13164
Target
-